This is a working overview of Ipamorelin, written for readers who want more than a one-paragraph summary but less than a textbook.
Reviewed 2025-08-31. Anything still debated is marked as such rather than presented as settled.
Ipamorelin is a synthetic pentapeptide that belongs to the growth hormone secretagogue family. Its sequence is Aib-His-D-2-Nal-D-Phe-Lys-NH2, incorporating two non-natural residues that resist enzymatic breakdown. Researchers at Novo Nordisk described the compound in the 1990s while searching for agents that release growth hormone with fewer side effects than earlier secretagogues. The molecule acts as an agonist at the ghrelin receptor, also called GHS-R1a, which is expressed in the pituitary and in several peripheral tissues.
Selectivity distinguishes ipamorelin from first-generation secretagogues such as GHRP-6. At doses that reliably raise growth hormone, it shows little stimulation of adrenocorticotropic hormone or cortisol release in animal models, and it does not markedly raise prolactin or appetite. Binding at GHS-R1a on pituitary somatotrophs triggers calcium influx and pulsatile growth hormone secretion. Because the compound mimics the natural ghrelin signal, the release pattern tends to follow the body's own rhythm rather than producing a sustained elevation.
Purity assessment for this peptide relies mainly on reversed-phase high-performance liquid chromatography. A C18 column with a water-acetonitrile gradient containing trifluoroacetic acid separates the target from truncated sequences and oxidation products. Detection near 214 nm exploits the amide backbone, while the aromatic side chains allow additional monitoring close to 280 nm. Reported purity values depend on the method, so a certificate of analysis carries weight only when gradient, column and integration parameters are given.
Mass spectrometry confirms identity and reveals structural deviations that chromatography alone can miss. Positive-mode electrospray ionisation generally yields multiply charged ions whose deconvoluted mass is checked against the theoretical value. Amino acid analysis, and enzymatic digestion with subsequent fragment mapping, provide independent confirmation of sequence and of the terminal amide. Analysts take care to separate the target from deletion sequences, which may differ by one residue and therefore by only a small mass increment.
| Property | Value | Notes |
|---|---|---|
| Molecular formula | C38H49N9O5 | Includes two non-natural residues |
| Molecular weight | About 711.9 g/mol | Confirmed by mass spectrometry |
| Appearance | White to off-white powder | Typical lyophilized form |
| Receptor target | GHS-R1a | Ghrelin receptor agonist |
| Plasma half-life | Roughly 2 hours | Varies by species and assay |
Ipamorelin is a synthetic pentapeptide that acts as an agonist at the ghrelin receptor, also called the growth hormone secretagogue receptor type 1a. Its sequence incorporates non-natural residues, which slows enzymatic breakdown relative to short native peptides. In laboratory and early clinical work the compound is described as a selective growth hormone secretagogue because it raises growth hormone with comparatively little effect on other pituitary outputs. The degree to which that selectivity holds across species and dosing regimens remains an open question in the published literature.
Signal transduction begins when the peptide binds GHSR-1a on pituitary somatotrophs. The receptor couples to Gq/11 proteins, activating phospholipase C, which cleaves phosphatidylinositol bisphosphate into inositol trisphosphate and diacylglycerol. Inositol trisphosphate releases calcium from intracellular stores, and the resulting rise in cytosolic calcium drives growth hormone vesicle fusion. Concurrent Gs coupling and cyclic AMP elevation have also been reported, and the relative contribution of each arm to the overall secretory response is not fully settled.
Ipamorelin is a synthetic pentapeptide first described in the 1990s by researchers at Novo Nordisk during a program to develop selective growth hormone secretagogues. Its sequence is Aib-His-D-2-Nal-D-Phe-Lys-NH2, incorporating two non-natural residues, alpha-aminoisobutyric acid and D-2-naphthylalanine. The C-terminus is amidated, and the material is supplied as a white lyophilized powder. The molecular formula is C38H49N9O5 and the monoisotopic mass is approximately 711.85 daltons. The short chain and modified residues give it greater resistance to enzymatic degradation than many larger peptide hormones.
At the molecular level, ipamorelin acts as an agonist at the growth hormone secretagogue receptor type 1a, the same G protein-coupled receptor that binds ghrelin. Receptor activation couples to Gq/11 signaling, raising intracellular calcium through inositol trisphosphate and diacylglycerol, which in turn promotes exocytosis of growth hormone from pituitary somatotroph cells. Ipamorelin binds this receptor with high affinity and shows weak activity at other secretagogue-related targets in vitro. Its action requires the intact receptor and is not reversed by growth hormone-releasing hormone antagonists.
=== 2016: Court of Arbitration for Sport verdict === On 12 January 2016, CAS handed down a guilty verdict on the thirty-four Essendon players, overturning the AFL Anti-Doping Tribunal's not-guilty verdict, after finding it was comfortably satisfied that the players were injected with Thymosin beta-4. Key to the appeal's success was the treatment of evidence: the CAS rejected the AFL Tribunal's approach, known as "links in the chain", where any individual chain of evidence is dismissed if any one link within it cannot be proven, and endorsed WADA's approach, known as "strands in the cable", where individual evidence chains with missing links may still be accepted if the combination of all such chains forms a sufficiently strong case. A complete account of the verdict and the arguments made by each side was released publicly. Vital to the case was determining whether or not the unspecified Thymosin used in the program was the banned Thymosin Beta-4 or a different, legal variety of Thymosin. A paper trail had confirmed that Dank had been dispensed Thymosin Beta-4 by the Como Compounding Pharmacy; however, no direct evidence was found that it was this Thymosin rather than a different legal Thymosin which had been administered to players, and this missing evidence link had been key to the AFL Tribunal's not guilty verdict under the 'links in the chain' method.
Barbiturates Benzodiazepines Ethanol (drinking alcohol; ethyl alcohol) Nonbenzodiazepines Others carisoprodol (Soma) chloral hydrate diethyl ether ethchlorvynol (Placidyl; "jelly-bellies") gamma-butyrolactone (GBL, a prodrug to GHB) gamma-hydroxybutyrate (GHB; G; Xyrem; "Liquid Ecstasy", "Fantasy") glutethimide (Doriden) kava (from Piper methysticum; contains kavalactones) ketamine, a phencyclidine (PCP) analog meprobamate (Miltown) methaqualone (Sopor, Mandrax; "Quaaludes") phenibut propofol (Diprivan), a general anesthetic theanine (found in Camellia sinensis, the tea plant) valerian (from Valeriana officinalis)
Polystyrene is commonly injection molded, vacuum formed, or extruded, while expanded polystyrene is either extruded or molded in a special process. Polystyrene copolymers are also produced; these contain one or more other monomers in addition to styrene. Expanded polystyrene composites with cellulose and starch have also been produced. Polystyrene is used in some polymer-bonded explosives (PBX).
Sources: en.wikipedia.org
==== Tax deduction for qualified overtime income ==== The law creates a new tax deduction of up to $12,500 ($25,000 if married filing jointly) of qualified overtime pay, effective January 1, 2025. A worker who is married but files separately from their spouse is not eligible for the tax deduction. A worker must have a social security number in order to be eligible for the tax deduction. Qualified overtime pay is compensation that an employer is required to pay an employee under the Fair Labor Standards Act, Section 7 because the employee worked more than 40 hours during the same workweek. The employee may take a tax deduction only for the extra half-time pay above their usual hourly rate they are paid for working more than 40 hours during the same workweek, not all the pay they receive for working those hours. Overtime paid that is either paid voluntarily by an employer, is paid based on contractual agreements, or is only required by state or local laws is not eligible for the tax deduction. The tax deduction begins to phase out for individuals whose modified adjusted gross income is more than $150,000 (or $300,000 if married filing jointly), and is eliminated at $400,000 (or $550,000 if married filing jointly). Individuals may take a tax deduction for the amount of qualified overtime compensation that appears on their Form W-2, up to annual limits. For 2025, employers may use a reasonable method to approximate the amount to put on a Form W-2 or via an alternate method.
"Midsize" fashion gained greater exposure on TikTok after many creators opened up about not able to find clothing sizes that fit them well. Women's apparel can roughly be divided into petite, straight, and plus sizes, leaving gaps in between. Realistic videos about how differently pieces of garment fit on a model compared to how they fit on a typical consumer resonated with many who had believed that they were alone in their struggle.
=== Category:EC 1.12 (act on hydrogen as a donor) === Category:EC 1.12.1 (with NAD+ or NADP+ as acceptor) Category:EC 1.12.2 (with a cytochrome as acceptor) Category:EC 1.12.5 (with a quinone or similar compound as acceptor) Category:EC 1.12.7 (with an iron–sulfur protein as acceptor) Category:EC 1.12.98 (with other known acceptors) Category:EC 1.12.99 (with other acceptors)
Sources: en.wikipedia.org
== Physiology == The activation of protein C is strongly promoted by thrombomodulin and endothelial protein C receptor (EPCR), the latter of which is found primarily on endothelial cells (cells on the inside of blood vessels). The presence of thrombomodulin accelerates activation by several orders of magnitude, and EPCR speeds up activation by a factor of 20. If either of these two proteins is absent in murine specimens, the mouse dies from excessive blood-clotting while still in an embryonic state. On the endothelium, APC performs a major role in regulating blood clotting, inflammation, and cell death (apoptosis). Because of the accelerating effect of thrombomodulin on the activation of protein C, the protein may be said to be activated not by thrombin but the thrombin–thrombomodulin (or even thrombin–thrombomodulin–EPCR) complex. Once in active form, APC may or may not remain bound to EPCR, to which it has approximately the same affinity as the protein zymogen. Protein C in zymogen form is present in normal adult human blood plasma at concentrations between 65 and 135 IU/dL. Activated protein C is found at levels approximately 2000 times lower than this. Mild protein C deficiency corresponds to plasma levels above 20 IU/dL, but below the normal range. Moderately severe deficiencies describe blood concentrations between 1 and 20 IU/dL; severe deficiencies yield levels of protein C that are below 1 IU/dL or are undetectable. Protein C levels in a healthy term infant average 40 IU/dL.
Reducing malnutrition is key part of the United Nations' Sustainable Development Goal 2 (SDG2), "Zero Hunger", which aims to reduce malnutrition, undernutrition, and stunted child growth. Managing severe acute undernutrition in a community setting has received significant research attention.
6-Hydroxynicotinate 3-monooxygenase (EC 1.14.13.114, NicC, 6HNA monooxygenase, HNA-3-monooxygenase) is an enzyme with systematic name 6-hydroxynicotinate,NADH:oxygen oxidoreductase (3-hydroxylating, decarboxylating). This enzyme catalyses the following chemical reaction
Sources: en.wikipedia.org
The peptide is Aib-His-D-2-Nal-D-Phe-Lys-NH2. Two of its residues are non-natural, which slows enzymatic degradation. The C-terminal amide is common among bioactive peptides.
It binds the same ghrelin receptor but with greater selectivity in functional assays. Preclinical work reports less cortisol and prolactin stimulation at growth-hormone-releasing doses. Those differences are relative, not absolute, and depend on dose and model.
No major regulatory authority has approved it for human therapeutic use. It is sold as a research chemical for laboratory investigation. Clinical status varies by country and is subject to change.
Results are most often expressed as a percentage of total peak area from a reversed-phase separation. That figure reflects the detection wavelength, gradient and integration choices used by the laboratory. Two valid certificates can therefore quote different values for the same material without either being incorrect.